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Concise review: isolation and characterization of cells from
human term placenta: outcome of the first international
Workshop on Placenta Derived Stem Cells
Abstract
Placental tissue draws great interest as a source of cells for regenerative medicine because of the
phenotypic plasticity of many of the cell types isolated from this tissue. Furthermore, placenta, which is
involved in maintaining fetal tolerance, contains cells that display immunomodulatory properties. These
two features could prove useful for future cell therapy-based clinical applications. Placental tissue is
readily available and easily procured without invasive procedures, and its use does not elicit ethical
debate. Numerous reports describing stem cells from different parts of the placenta, using nearly as
numerous isolation and characterization procedures, have been published. Considering the complexity
of the placenta, an urgent need exists to define, as clearly as possible, the region of origin and methods
of isolation of cells derived from this tissue. On March 23-24, 2007, the first international Workshop on
Placenta Derived Stem Cells was held in Brescia, Italy. Most of the research published in this area
focuses on mesenchymal stromal cells isolated from various parts of the placenta or epithelial cells
isolated from amniotic membrane. The aim of this review is to summarize and provide the state of the
art of research in this field, addressing aspects such as cell isolation protocols and characteristics of
these cells, as well as providing preliminary indications of the possibilities for use of these cells in future
clinical applications
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ABSTRACT 
Placental tissue draws great interest as a source of 
cells for regenerative medicine because of the 
phenotypic plasticity of many of the cells types 
isolated from this tissue. Furthermore, placenta, 
which is involved in maintaining fetal tolerance, 
contains cells which display immunomodulatory 
properties. These two features could prove useful for 
future cell therapy-based clinical applications. 
Placental tissue is readily available and easily 
procured without invasive procedures, and its use 
does not elicit ethical debate. 
Numerous reports describing stem cells from 
different parts of the placenta have been published, 
using nearly as numerous isolation and 
characterization procedures. 
Considering the complexity of the placenta, an 
urgent need exists to define, as clearly as possible, the 
region of origin and methods of isolation of cells 
derived from this tissue. 
On March 23rd-24th, 2007, the first international 
“Workshop on Placenta Derived Stem Cells” was 
held in Brescia, Italy. 
Most of the research published in this area focuses on 
mesenchymal stromal cells isolated from various 
parts of the placenta or epithelial cells isolated from 
amniotic membrane. The aim of this review is to 
summarize and provide the state of the art of 
research in this field, addressing aspects including 
cell isolation protocols and characteristics of these 
cells, as well as providing preliminary indications of 
the possibilities for use of these cells in future clinical 
applications. 
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INTRODUCTION 
 
Human placenta, besides playing a 
fundamental and essential role in fetal 
development, nutrition and tolerance, may also 
represent a reserve of progenitor/stem cells. 
 
Considering the complexity of the structure of 
the placenta, we have focused our attention on 
cells isolated from the amniotic and chorionic 
fetal membranes and reached a consensus on 
the minimal criteria for definition of 
mesenchymal cells derived from both of these 
membranes. 
 
Cord blood and amniotic fluid-derived cells are 
not included in this discussion. 
 
From the data presented by the participants, it 
was evident that: 
 
Cells isolated from placental tissue should be 
verified to be of fetal origin (using methods 
sensitive enough to detect maternal 
contamination of 1% or less). 
 
Four regions of fetal placenta can be 
distinguished: amniotic epithelial, amniotic 
mesenchymal, chorionic mesenchymal, and 
chorionic trophoblastic. From these regions, 
the following cell populations are isolated: 
human Amniotic Epithelial Cells (hAEC), 
Amniotic Mesenchymal Stromal Cells 
(hAMSC), Chorionic Mesenchymal Stromal 
Cells (hCMSC), and Chorionic Trophoblastic 
Cells (hCTC). 
 
Cells from each layer demonstrate variable 
plasticity. Because of their plasticity, the term 
stem cell has been used in the literature to 
describe a number of cells isolated from 
placenta. Self renewal and “hierarchy” which 
are normally considered a hallmark of stem 
cells have not been clearly demonstrated in the 
different placenta derived cell types, and 
therefore the term ‘stem cell’ at this time is not 
always appropriate. However it may be 
interesting to mention that recent reports 
propose an alternative stem cell concept 
whereby plasticity is essential to define 
stemness and self renewal and hierarchy are 
optional characteristics [1, 2]. 
 
According to criteria recently proposed by 
Dominici for bone marrow-derived 
mesenchymal stromal cells (BM-MSC) [3], 
mesenchymal cells isolated from fetal 
membranes should be termed mesenchymal 
stromal cells (hAMSC and hCMSC). 
 
Minimal criteria for defining hAMSC and 
hCMSC are: 
 
Adherence to plastic 
 
Formation of fibroblast colony forming units 
(CFU-F) 
 
A specific pattern of surface antigen expression 
(Table 1) 
 
Differentiation potential toward one or more 
lineages including: osteogenic, adipogenic, 
chondrogenic, vascular/endothelial 
 
Fetal origin 
 
The participants of the workshop concluded 
that placenta is an important source of 
stem/progenitor cells, and additional useful cell 
types in this tissue may yet be defined. Here, 
we briefly describe the structure of this organ 
and discuss isolation, characterization and 
differentiation protocols for hAEC, hAMSC 
and hCMSC, as well as the immunomodulatory 
properties, in vitro and in vivo preclinical 
studies and cell banking strategies for these 
cell populations. We do not include hCTC in 
our discussion as very little definitive 
information has been published on these cells 
to date. 
 
1. The placenta 
1.1 Placental compartments 
The fetal adnexa is composed of the placenta, 
fetal membranes and umbilical cord. The term 
placenta is discoid in shape with a diameter of 
15-20 cm and a thickness of 2-3 cm. From the 
margins of the chorionic disc extend the fetal 
membranes, amnion and chorion, which 
enclose the fetus in the amniotic cavity, and the 
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endometrial decidua. The chorionic plate 
(Figure 1) is a multilayered structure which 
faces the amniotic cavity. It consists of two 
different structures: the amniotic membrane 
(composed of epithelium, compact layer, 
amniotic mesoderm and spongy layer) and the 
chorion (composed of mesenchyme and a 
region of extravillous proliferating trophoblast 
cells interposed in varying amounts of 
Langhans fibrinoid, either covered or not by 
syncytiotrophoblast). Villi originate from the 
chorionic plate and anchor the placenta through 
the trophoblast of the basal plate and maternal 
endometrium. From the maternal side, 
protrusions of the basal plate within the 
chorionic villi produce the placental septa, 
which divide the parenchyma into irregular 
cotyledons (Figure 1). 
 
Some villi anchor the placenta to the basal 
plate, while others terminate freely in the 
intervillous space. Chorionic villi present with 
different functions and structure. In the term 
placenta, the stem villi show an inner core of 
fetal vessels with a distinct muscular wall, and 
connective tissue consisting of fibroblasts, 
myofibroblasts, and dispersed tissue 
macrophages (Hofbauer cells). Mature 
intermediate villi and term villi are composed 
of capillary vessels and thin mesenchyme. A 
basement membrane separates the stromal core 
from an uninterrupted multinucleated layer, 
called syncytiotrophoblast. Between the 
syncytiotrophoblast and its basement 
membrane are single or aggregated Langhans’ 
cytotrophoblastic cells, commonly called 
cytotrophoblast cells. 
 
Fetal membranes continue from the edge of the 
placenta and enclose the amniotic fluid and the 
fetus. The amnion is a thin, avascular 
membrane composed of an epithelial layer and 
an outer layer of connective tissue, and is 
contiguous, over the umbilical cord, with the 
fetal skin. The amniotic epithelium (AE) is an 
uninterrupted, single layer of flat, cuboidal and 
columnar epithelial cells in contact with 
amniotic fluid. It is attached to a distinct basal 
lamina that is, in turn, connected to the 
amniotic mesoderm (AM) (Figure 2). In the 
amniotic mesoderm closest to the epithelium, 
an acellular compact layer is distinguishable, 
composed of collagens I, III and fibronectin. 
Deeper in the AM, a network of dispersed 
fibroblast-like mesenchymal cells and rare 
macrophages are observed. Very recently, it 
has been reported that the mesenchymal layer 
of amnion indeed contains two subfractions, 
one having a mesenchymal phenotype which is 
referred throughout this review as amniotic 
mesenchymal stromal cells (AMSC), and the 
second containing monocyte-like cells [4]. 
 
A spongy layer of loosely arranged collagen 
fibers separates the amniotic and chorionic 
mesoderm (Figure 2). The chorionic membrane 
(chorion leave) consists of mesodermal (CM) 
and trophoblastic (CT) regions (Figure 2). 
Chorionic and amniotic mesoderm are similar 
in composition. A large and incomplete basal 
lamina separates the chorionic mesoderm from 
the extravillous trophoblast cells. The latter, 
similar to trophoblast cells present in the basal 
plate, are dispersed within the fibrinoid layer 
and express immunohistochemical markers of 
proliferation. The Langhans’ fibrinoid layer 
usually increases during pregnancy and is 
composed of two different types: a matrix type 
on the inner side (more compact) and a fibrin 
type on the outer side (more reticulate). At the 
edge of the placenta and in the basal plate, the 
trophoblast interdigitates extensively with the 
deciduas [5, 6]. 
 
1.2 Embryological development 
In humans, by day 6-7 after fertilization 
(during the implantation window), the 
blastocyst implants and placenta development 
begins. At this stage, the blastocyst is flattened 
and composed of an outer wall (trophoblast) 
which surrounds the blastocystic cavity. A 
small group of larger cells, the inner cell mass, 
is apposed to the inner surface of the 
trophoblastic vesicle. The embryo, umbilical 
cord and amniotic epithelium are derived from 
the inner cell mass. As the blastocyst adheres 
to the endometrium, invading trophoblasts 
erode the decidua, facilitating implantation of 
the blastocyst. By 8-9 days after fertilization, 
trophoblastic cells at the implanting pole of the 
blastocyst proliferate robustly, forming a 
bilayered trophoblast. The outer of the two 
layers becomes the syncytiotrophoblast by 
fusion of neighboring trophoblast cells, while 
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the inner cells (cytotrophoblast) remain 
temporally unfused. 
 
The proliferating cytotrophoblasts and the 
syncytiotrophoblasts give rise to a system of 
trabeculae intermingled with hematic lacunae. 
From these trabeculae are generated the 
primordial villi which are distributed over the 
entire periphery of the chorionic membrane. 
Villi in contact with the decidua basalis 
proliferate to form the leafy chorion or chorion 
frondosum, while villi in contact with the 
decidua capsularis degenerate into the chorion 
leave. 
 
At day 8-9 after fertilization, the inner cell 
mass differentiates into two layers: the epiblast 
and the hypoblast. Subsequently, from the 
epiblast, small cells that later constitute the 
amniotic epithelium appear between the 
trophoblast and the embryonic disc and enclose 
a space that will become the amniotic cavity. 
On the opposite side, between the hypoblast 
and cytotrophoblast, the exocoelomic 
membrane and its cavity modify to form the 
yolk sac. The extraembryonic mesoderm 
arranges into a connective tissue that surrounds 
the yolk sac and amniotic cavity, giving rise to 
amniotic and chorionic mesoderm. 
Gastrulation, the process through which the 
bilaminar disc differentiates into the three germ 
layers (ectoderm, mesoderm and endoderm) 
and develops a defined form, with a midline, 
cranio-caudal, right-left and dorsal-ventral 
body axes, occurs during the third week after 
fertilization [6, 7]. 
 
2. Fetal Placenta Tissue Cell Populations 
2.1 Human Amniotic Epithelial Cells 
Recent reports indicate that human amniotic 
epithelial cells (hAEC) express stem cell 
markers and have the ability to differentiate 
toward all three germ layers. These properties, 
the ease of isolation of the cells, and the 
availability of placenta as a discard tissue, 
make the amnion a potentially useful and 
noncontroversial source of cells for 
transplantation and regenerative medicine. For 
isolation of epithelial cells, the amniotic 
membrane is stripped from the underlying 
chorion and digested with trypsin or other 
digestive enzymes (Table 2) [8-11]. Epithelial 
cells are specifically released by brief trypsin 
digests of 20-40 minutes each. A detailed 
protocol is available providing a step by step 
isolation procedure along with photos of the 
process [12]. Isolated cells readily attach to 
plastic or basement membrane-coated culture 
dishes. Culture is commonly established in a 
simple media such as DMEM supplemented 
with 5-10% serum and epidermal growth factor 
(EGF) (Table 2), where the cells proliferate 
robustly and display typical cuboidal epithelial 
morphology [10, 11, 13]. Normally, 2-6 
passages are possible before proliferation 
ceases. Cells do not proliferate well at low 
densities. Amniotic membrane contains 
epithelial cells with different surface markers, 
suggesting some heterogeneity of phenotype. 
Immediately after isolation, hAEC appear to 
express very low levels of HLA- A,B,C [10], 
however, by passage 2, significant levels are 
observed (Table 2). Additional cell surface 
antigens on hAEC include ATP-binding 
cassette transporter G2 (ABCG2/BCRP), CD9, 
CD24, E-cadherin, integrins alpha 6 and beta 1, 
c-met (HGF receptor), stage specific 
embryonic antigens (SSEA) 3 and 4 and tumor 
rejection antigens (TRA) 1-60 and 1-81 [11, 
14]. Surface markers thought to be absent on 
hAEC include SSEA-1, CD34, and CD133, 
while other markers such as CD117 (c-kit) and 
CCR4 (CC chemokine receptor) are either 
negative or may be expressed on some cells at 
very low levels. Although initial cell isolates 
express very low levels of CD90 (Thy-1), the 
expression of this antigen increases rapidly in 
culture [11, 14]. Additional surface markers are 
presented in Table 2. 
 
In addition to surface markers, hAEC express 
molecular markers of pluripotent stem cells, 
including octamer-binding-protein-4 (OCT-4), 
SRY-related HMG-box gene 2 (SOX-2), and 
Nanog [11]. The suggestion that hAEC may be 
pluripotent was supported by the report by 
Tamagawa et al. [15]. These investigators 
created a xenogeneic chimera of human 
amnion cells with mouse embryonic stem cells, 
in vitro. Chimeric aggregates were maintained 
and human contribution to all three germ layers 
was established. Later studies indicated that 
differentiation of hAEC can be directed. 
Sakuragawa and co-workers identified neural 
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and glial markers on cultured hAEC [16]. Later 
studies reported that cultured hAEC synthesize 
and release acetylcholine, catecholamines [9, 
17, 18] and dopamine [19, 20]. Hepatic 
differentiation of hAEC was also reported. 
Sakuragawa et al. [21] reported that cultured 
hAEC produce albumin (Alb) and α-
fetoprotein (AFP), and that Alb- and AFP-
positive hepatocyte-like cells could be 
identified integrated into hepatic parenchyma 
following transplantation of hAEC into the 
livers of severe combined immunodeficiency 
(SCID) mice. The hepatic potential of hAEC 
was confirmed and extended [11, 22, 23] 
whereby in addition to Alb and AFP 
production, other hepatic functions such as 
glycogen storage and expression of liver 
enriched transcription factors such as 
hepatocyte nuclear factor (HNF) 3γ and 
HNF4α, CCAAT/enhancer-binding protein 
(CEBP α and β) and several of the drug 
metabolizing genes, cytochrome P450, could 
be demonstrated. The wide range of hepatic 
genes and functions identified in hAEC 
suggests that these cells may be useful for 
liver-directed cell therapy. 
 
Differentiation of hAEC to another endodermal 
tissue, pancreas, was also reported. Wei et al. 
[24] cultured hAEC for 2-4 weeks in the 
presence of nicotinamide to induce pancreatic 
differentiation. Subsequent transplantation of 
the insulin-expressing hAEC corrected the 
hyperglycemia of streptozotocin-induced 
diabetic mice. In the same setting, hAMSC 
were ineffective, suggesting that hAEC, but not 
hAMSC, were capable of acquiring a β-cell 
fate. 
 
Studies reviewed above indicate that hAEC are 
unique cells with many stem cell 
characteristics. Cell types from all three germ 
layers were produced in vitro. There is 
currently strong in vitro and in vivo evidence of 
neural, pancreatic and hepatic differentiation of 
hAEC. 
 
2.2 Mesenchymal Stromal Cells from 
Amnion and Chorion: hAMSC and hCMSC 
Human amniotic and chorionic mesenchymal 
stromal cells (hAMSC and hCSMC) are 
thought to be derived from extraembryonic 
mesoderm [7]. Extensive phenotypical and 
functional characterization is available on 
hAMSC [25-29], while few report 
investigations on hCMSC [28, 30, 31]. 
 
hAMSC and hCMSC can be isolated from 
first-, second- and third-trimester mesoderm of 
amnion and chorion, respectively [25-29, 31]. 
Here, when using the terms hAMSC and 
hCMSC we refer to cells from term placenta 
unless otherwise specified. For hAMSC, 
isolations are usually performed with term 
amnion dissected from the deflected part of the 
fetal membranes to minimize the presence of 
maternal cells. Homogenous hAMSC 
populations can be obtained by a two-step 
procedure: minced amnion tissue is treated 
with trypsin to remove hAEC, and remaining 
mesenchymal cells are then released by 
digestion with collagenase [32], or collagenase 
and DNase [33]. The yield from term amnion 
is about 1 million hAMSC and 10-fold more 
hAEC per gram of tissue [33]. 
 
hCMSC are isolated from both first- and third- 
trimester chorion after mechanical and 
enzymatic removal of the trophoblastic layer 
with dispase. Chorionic mesodermal tissue is 
then digested with collagenase [28] or 
collagenase plus DNAse [31]. Mesenchymal 
cells have also been isolated from chorionic 
fetal villi through explant culture, although 
maternal contamination is more likely [30, 31, 
34]. 
 
Both hAMSC and hCMSC adhere and 
proliferate on tissue culture plastic, and can be 
kept until passage 5-10. Reports suggest that 
hAMSC proliferation slows beyond passage 2, 
although both first-trimester hAMSC and 
hCMSC proliferate better than third-trimester 
cells [28]. Theoretically, term amnion may 
yield up to 5 x 108 hAMSCs [35], however in 
practice, yields are typically 4 million 
hAMSC/100 cm2 starting material with a 4-
fold expansion after one-month (2 passages) 
(G. Bilic, S. Zeisberger, A.H. Zisch, 
unpublished data). 
 
Phase micrographs (Figure 3) show the distinct 
morphology of cultured hAMSC, hCMSC and 
hAEC. Expression of CD49d (α4 integrin) on 
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hAMSC distinguishes them from hAEC [29]. 
In culture, neither vimentin nor cytokeratin 18 
expression are specific for hAMSC or hAEC, 
respectively. Transmission electron 
microscopy of hAMSC shows mesenchymal 
and epithelial characteristics. This hybrid 
phenotype is interpreted as a sign of 
multipotentiality and is not found in hCMSC, 
which are more primitive and metabolically 
quiescient. Specifically, when compared to 
hAMSC, transmission electron microscopy of 
hCMSC show a simpler cytoplasmic 
organization. The most relevant features 
include the presence of stacks of rough 
endoplasmic reticulum cisternae, dispersed 
mitochondria and glycogen lakes, while 
features of higher specialization, such as 
presence of assembled contractile filaments, 
prominence of endocytotic traffic and 
junctional comunications, are lacking. Overall, 
the ultrastructural characteristics of hCMSC 
resemble those found in the haematopoietic 
progenitors and in the blue small round cell 
tumors, e.g., Ewing sarcomas, suggesting their 
position at the higher levels of the stem cell 
hierarchy [36]. The surface marker profile of 
cultured hAMSC, hCMSC and MSC from 
adult bone marrow are similar. All express 
typical mesenchymal markers (Table 1) but are 
negative for hematopoietic (CD34 and CD45) 
and monocytic markers (CD14) [26, 28, 29, 
31]. Surface expression of stage specific 
embryonic antigens SSEA-3 and SSEA-4 and 
RNA for OCT-4 has been reported [24, 29, 35, 
37] (G. Bilic, S. Zeisberger, A.H. Zisch, 
unpublished data). However, 
immunofluorescence staining of mesenchyme 
tissue did not detect SSEA-3 or SSEA-4 [38]. 
Both first- and third- trimester hAMSC and 
hCMSC express low levels of HLA-ABC, but 
not HLA-DR, [28, 29] indicating an 
immunoprivileged status. 
 
Both hAMSC and hCMSC differentiate toward 
“classic” mesodermal lineages (osteogenic, 
chondrogenic and adipogenic) [26, 28, 29, 31, 
35], and differentiation of hAMSC to all three 
germ layers - ectoderm (neural), mesoderm 
(skeletal muscle, cardiomyocytic and 
endothelial) and endoderm (pancreatic) - was 
reported (Table 3). Questions remain as to the 
proportion of hAMSC that exhibit plasticity 
and the full maturation of progeny [39]. 
 
Human amniotic and chorionic cells 
successfully and persistently engraft in 
multiple organs and tissues in vivo. Human 
chimerism detection in brain, lung, bone 
marrow, thymus, spleen, kidney and liver after 
either IP or IV transplantation of human 
amnion and chorion cells into neonatal swine 
and rats was indeed indicative of an active 
migration consistent with the expression of 
adhesion and migration molecules (L-selectin, 
VLA-5, CD29, P-selectin Ligand 1), as well as 
cellular matrix proteinases (MMP-2 and MMP-
9) [40]. 
 
3. Immunology of the Placenta 
Maternal acceptance of the fetal allograft is not 
completely understood. The paradox of 
maternal tolerance of the fetus was first raised 
more than 50 years ago by Peter Medawar, 
who proposed that: i) there is a physical 
separation between the mother and fetus, ii) the 
fetus is antigenically immature, and iii) the 
mother possesses an immunological inertness 
[41]. 
 
Since the time of Medawar, several 
mechanisms that contribute to tolerance 
induction have been proposed, although how 
they are regulated and driven to interact with 
each other remain unclear. 
 
In particular, different explanations have been 
proposed regarding the regulation of maternal 
T cell proliferation at the fetal maternal 
interface. It has been shown that some cells of 
the syncytiotrophoblast express the tryptophan 
catabolising enzyme IDO (indoleamine 2,3-
dioxygenase), resulting in the depletion of 
tryptophan and inhibition of T cell 
proliferation, which may provide protection of 
the fetus from maternal T cells [42, 43]. 
However, in IDO knockout mice fetus 
rejection was not observed [44]. Therefore, 
even though IDO activity has been 
hypothesized as a key mechanism for 
protecting the allogenic fetus, it is not the sole 
determinant since other mechanisms, perhaps 
redundant in normal mice, can compensate for 
the loss of IDO activity during gestation. 
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Furthermore, soluble HLA-G molecules 
produced by placenta induce apoptosis of 
activated CD8+ T cells [45] and inhibit CD4+ 
T cell proliferation [46]. Trophoblast cells 
expressing HLA-G may also inhibit Natural 
Killer cells which could induce fetal rejection 
[47]. In addition, trophoblast cells which 
express Fas ligand (CD95L) have been 
demonstrated to induce apoptosis of maternal 
Fas (CD95)-expressing lymphocytes [48], 
therefore representing another possible 
mechanism for contributing to the maintenance 
of fetomaternal tolerance. 
 
The mechanisms discussed above are not 
definitive and it is very likely that they all play 
a role in the complex phenomenon of fetal 
maternal tolerance. 
 
3.1 Role of fetal membranes in tolerance 
It has been proposed that cells from fetal 
membranes have immunoregulatory properties. 
 
Amniotic membrane and hAEC are used on 
skin wounds, burn injuries, chronic leg ulcers, 
and to prevent adhesions in surgical procedures 
[49-55]. Amniotic membrane is also used in 
ocular surface reconstruction to promote 
development of normal corneal or conjunctival 
epithelium [56] without immunosuppression or 
acute rejection. Furthermore, transplantation of 
allogenic amniotic membrane or hAEC without 
immunosuppression does not induce acute 
immune rejection [8, 57-60]. In vitro studies 
show that cells isolated from amniotic and 
chorionic membranes do not elicit an 
allogeneic or xenogeneic immune response, but 
actively suppress lymphocyte proliferation [29, 
40, 61]. Human amniotic membrane and hAEC 
have been shown to survive for prolonged 
times in immuno-competent animals, including 
rabbits [62], rats [63], guinea pigs [64] and 
bonnet monkeys [65]. Additionally, long-term 
engraftment was observed after intravenous 
injection of heterogeneous human 
amniochorionic cells into newborn swine and 
rats, with human microchimerism detected in 
bone marrow, brain, lung and thymus [40], 
suggesting active migration and integration 
into specific organs, and indicating active 
tolerance of the xenogeneic cells. 
4. Placenta as a potent niche source for 
hematopoietic stem/progenitor cells: 
Insights from the mouse placenta 
In mouse placenta the allantois, an extension of 
the primitive streak, fuses with the chorionic 
plate, giving rise to umbilical vasculatures and 
mesoderm of fetal placenta. Allantoic 
mesoderm interdigitates with trophoblasts to 
form the placenta labyrinth. Allantois-derived 
umbilical arteries are the site of hematopoietic 
stem cell (HSC) ontogeny. In 1961, Till and 
McCulloch reported that placenta harbors 
transplantable hematopoietic activity [66]. 
Melchers detected B cell progenitors in 
placenta prior to their appearance in fetal liver 
[67]. Multi-potential myeloerythroid 
progenitors are present at a higher frequency in 
mouse placenta than in yolk sac or fetal liver 
[68]. Mouse placenta is a niche for developing 
HSCs without facilitating myeloid or erythroid 
differentiation. The distribution of HSC in 
placenta and the aorta-gonad-mesonephros 
region was compared and a dramatic expansion 
of placenta HSC (50 HSC-long-term 
repopulating units per organ) was reported at 
E12.5 [69] and HSC were detected in the 
vascular labyrinth of placenta of Ly-6A (Sca-1) 
GFP transgenic mice [70]. Hematopoietic 
cytokines produced by human placental MSC, 
such as stem cell factor (SCF), Flt 3 ligand 
(FL), IL-6, and macrophage colony stimulating 
factor (M-CSF), functionally support a 7-fold 
expansion of long-term culture-initiating cells 
(LTC-IC) [71] and additional factors were 
identified and cloned [72]. 
 
Mouse placenta serves as a source and a 
functional niche for HSC [73]. Pre-fusion 
allantois and chorion are potent sources for 
hematopoietic progenitors. Allantois and 
chorion, isolated prior to the union between the 
three major circulatory systems (umbilical 
cord, yolk sac and cardiovascular) in the 
conceptus, express Runx1, a key 
transcriptional factor critical for HSC 
ontogeny, and CD41, a hallmark for initiation 
of definitive hematopoiesis [74], and also 
generate myeloid and definitive erythroid 
lineages following explant culture [75]. 
Furthermore, hemogenic potential and Runx1 
expression are independent of the union of the 
tissues, reflecting their intrinsic hematopoietic 
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property. The identification of critical niche 
components for HSCs from placenta may be 
useful for ex vivo HSC expansion. 
 
5. Preclinical studies in animal models 
5.1 Hepatic regeneration 
Hepatocyte transplantation has become a novel 
method for treatment of liver disease [76]. 
However, the technique is currently limited by 
a shortage of suitable hepatocytes for 
transplant procedures. The large number of 
hepatic genes and functions identified in hAE 
suggest that if effective and efficient methods 
were developed to induce complete hepatic 
differentiation, hAE could be a useful source of 
cells for transplant procedures. Preclinical 
investigations with hepatic differentiation of 
hAEC have been promising. In vitro, 
differentiation procedures have yielded cells 
which express a number of liver functions 
including the transcription factors HNF3γ, and 
C/EBPα, HNF-1, HNF-4α, pregnane x 
receptor and constitutive androstane receptor, 
and differentiated liver genes including 
albumin, α1-antitrypsin (A1AT), glucose-6-
phosphatase, carbamoyl phosphate synthase I 
(CPS-I), glutamine synthase (GS), 
phosphoenolpyruvate carboxykinase (PEPCK), 
tyrosine aminotransferase (TAT), transthyretin 
(TTR) and the drug metabolizing genes 
CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2D6 2E1, 
3A4 and 7 and 7A1 [11, 14, 22, 23]. In 
addition to quantification of RNA, drug 
metabolism dependent on CYP1A and CYP3A 
enzymatic activity was demonstrated [11, 77]. 
In unpublished work, the list of hepatic genes 
identified in hAE include transport proteins 
including p-glycoprotein, multidrug resistance 
protein 1, ABCG2, the bile salt export pump 
(BSEP), uridine diphosphate glucuronosyl 
transferase 1A1 (UGT1A1) and ornithine 
transcarbamylase (OTC) (Strom, et al., 
unpublished). Following transplantation into 
the liver, successful engraftment and survival 
of human [21, 77] or rat AEC [78] has been 
demonstrated. Recent unpublished work 
extends these observations to more than 6 
months. Human A1AT could be detected by 
western blot in mouse serum [14] clearly 
indicating that hAEC perform this important 
hepatic function in vivo. Human albumin was 
detected in the sera and peritoneal fluid of 
SCID mice who received peritoneal implants 
of human amniotic membrane [22]. At this 
time there are no reports of the characterization 
of hepatic gene expression in long-term 
recipients of AE transplants, or that the 
transplantation of AEC can support animals 
with acute or long-term defects in liver 
function. These important preclinical studies 
will be needed before the therapeutic potential 
of hAE can be fully assessed. 
 
At least 30 genes known to be expressed in 
mature human liver are expressed in hAE 
directed towards hepatic differentiation in 
culture, suggesting that transplantation of hAE-
derived hepatocytes could be an effective 
therapy for liver disease. It is significant that 
among the hepatic genes expressed are A1AT, 
OTC, CPS-I and UGT1A1. Mutations in these 
genes cause metabolic liver diseases which are 
currently corrected by liver transplantation. 
Perhaps hAEC transplants could provide a 
novel cell therapy for patients suffering liver or 
lung disease from A1AT deficiency, or those at 
risk of neurological effects due to the inability 
to metabolize and excrete ammonia (OTC and 
CPS-I) or bilirubin (UGT1A1). 
 
5.2 Cardiac Repair 
Myocardial infarction, ischemia, and stroke are 
important consequences of end-stage occlusive 
vascular disease. Present-day therapies are 
inadequate and palliative, so stem cell therapy 
has been investigated. Co-culture experiments 
with neonatal rat heart explants have confirmed 
that hAMSC integrate into cardiac tissues and 
differentiate into cardiomyocyte-like cells. 
After transplantation into myocardial infarcts 
in rat hearts, hAMSC survived for 2 months 
and differentiated into cardiomyocyte-like cells 
[37]. 
 
A mixed ester of hyaluronan, butyric and 
retinoic acids (HBR) was reported to promote 
cardiogenic/vasculogenic differentiation of 
human amniochorionic (AC)-derived cells. 
HBR enhanced the expression of 
cardiomyogenic genes (GATA4, NKX 2.5) and 
proteins (sarcomeric myosin heavy chain and 
a-sarcomeric actinin) but not skeletal muscle 
myosin D (MyoD) or neurogenic features 
(Neurogenin). Cells treated with HBR express 
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both cardiac and endothelial markers such as 
von Willebrand factor (vWF), and enhance 
cardiac repair in infarcted rat heart. AC 
transplants increase capillary density at the 
infarct border, normalize left ventricular 
function, and decrease scar formation. 
Transplantation of HBR-preconditioned AC-
derived cells further enhanced capillary density 
and the yield of human vWF-expressing cells, 
additionally decreasing the infarct size. Some 
engrafted, HBR-pretreated AC-derived cells 
were also positive for connexin 43 and cardiac 
troponin I. These improvements may be related 
to the local or paracrine secretion of 
angiogenic, antiapoptotic and mitogenic factors 
following hMSC transplantation, in addition to 
the differentiation of AC to vascular cells. 
These “trophic” effects may provide major 
contribution to the therapeutic potential of 
MSCs for myocardial infarction and dilated 
cardiomyopathy. These findings provide an 
innovative approach to cell therapy of heart 
failure, whereby AC secrete trophic factors and 
under the influence of HBR, may show 
enhanced cardiac and vascular differentiation 
[35, 79]. 
 
5.3 Placenta derived stem cells for treating 
neurological disorders 
Human AEC have shown particular potential 
for treating central nervous system disorders. 
Since the discovery that hAEC have stem cell 
properties [11], express neural and glial 
markers and neural-specific proteins, and also 
have the capacity to produce and secrete 
neurotransmitters [9, 17], cell therapy with 
these cells has been considered [9, 16]. 
Successful transplants of hAEC into caudate 
nucleus [19, 20, 80], hippocampus [81] and 
spinal cord [65] have been reported. 
Transplantation of hAEC in a rat model of 
Parkinson’s reversed the condition and 
prevented neuronal death [19, 20]. When 
hAEC were transplanted into ischemic 
hippocampus, they differentiated into “neuron-
like” cells [81]. Following transplantion into 
the transected spinal cord of monkeys, hAEC 
aided a robust regeneration of host axons and 
prevented death of axotomised neurons of the 
spinal cord [65]. Transplantation of hAEC into 
the lesioned areas of a contusion model of 
Spinal Cord Injury (SCI) in rats was performed 
without immunosuppression. Cells survived up 
to 120 days with no evidence of inflammation 
or rejection. Animals showed gradual 
functional improvement using the Basso, 
Beattie and Brensnahan (BBB) locomotor 
rating scale, and ultimately reached a score of 
19, just two points below normal animals. 
Improvement was also observed in control 
animals, however, improvement was faster 
during acute and sub-acute phases of recovery 
in transplant recipients. Zhi-yuan et al. (2006) 
reported similar findings [82]. Early 
improvement in the BBB scale is thought to 
indicate that hAEC provide neuroprotection 
[83]. In narrow beam and inclined plane tests, 
the performance of hAEC-transplanted animals 
was significantly improved when compared 
with lesion control animals. These tests 
measure cortico-spinal tract [84] and 
rubrospinal tract [85, 86] function, 
respectively. Improvement following hAEC 
transplants indicates improvement of 
pyramidal (cortico-spinal) and extra-pyramidal 
(brain stem) systems of motor tracts controlling 
locomotion. Human AEC secrete neurotrophic 
factors [87], while medium conditioned by 
hAEC has been shown to be neurotrophic for 
E18 rat cortical cells. Novel EGF-like 
neurotrophic factors were thought to mediate 
this effect [88]. hAEC conditioned medium 
also supported survival of E10 chicken neural 
retinal cells, which were otherwise dependent 
on fibroblast growth factor-2 (FGF-2) [89, 90]. 
Although FGF-2 and EGF were not detected in 
media by immunoblotting, FGF-2 and EGF 
gene and protein expression was reported in 
cryopreserved hAEC [88, 91]. Recently, MSCs 
were found to produce “neuron-like” cells, but 
their function is yet to be proven [92]. 
 
In conclusion, hAEC transplants produce 
beneficial results in animal models of spinal 
cord injury. They were found to exhibit 
neuroprotection in acute phases of injury and 
facilitate regeneration of long tracts in long-
term phases of recovery, as measured by 
behavioural assessment. The beneficial effects 
may be mediated through the secretion of 
novel neurotrophic factors. 
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5.4 Cell tracking 
In preclinical studies, tracking of transplanted 
cells is essential. Using cell labeling together 
with imaging, cells can be traced non-
invasively [93-101]. Stem cells from different 
sources have been labeled using radionuclides, 
magnetic nanoparticles or reporter genes, both 
in preclinical and clinical studies [94, 102, 
103]. In contrast to other imaging techniques, 
luminescence imaging detects live cells since 
the reporter gene, luciferase, generates photon 
emission only in presence of ATP, luciferin 
and oxygen [104]. Reporter gene transfection 
protocols established for adipose-derived stem 
cells have been successfully applied in hAMSC 
[101], allowing luminescence imaging of their 
survival, migration and distribution in 
preclinical in vivo models. 
 
6. Cell and Tissue Banking 
6.1 General aspects of banking for human 
use 
Cell or tissue banking follows specific rules. 
EC directive 2003/94/EC lays down the 
principles and guidelines of good 
manufacturing practice (GMP) for medicinal 
products for human use. This directive is 
particularized in the so-called GMP Guidelines 
[105]. Standards of quality and safety for the 
donation, procurement, testing, processing, 
preservation, storage and distribution of human 
tissues and cells, with annotations to 
traceability, adverse reactions and technical 
requirements concerning production and 
quality control, are found in directive 
2004/23/EC and specified in 2006/17/EC and 
2006/86/EC. Other institutions (e.g. EATB, 
JACIE) also publish standards for cell and 
tissue banking and interpreting laws [106, 107, 
108]. 
 
6.2 Cell Banking 
So far, most experience in preservation of 
placental tissue-derived cells has been gained 
with cord blood, which contains both 
hematopoietic and mesenchymal stem cells. 
When cord blood transplantation proved 
effective, many cord blood banks were 
established, offering collection and banking for 
public (allogeneic) or private (autologous or 
allogeneic) use. Cord blood is procured from 
natural births or caesarean sections [109]. 
Different methods for the reduction of red 
blood cells, plasma volume and 
cryopreservation exist [110]. Cord blood 
products containing cryoprotectants (e.g. 
DMSO) are frozen at a controlled-rate and can 
be stored in liquid nitrogen for at least 15 years 
without the loss of their engraftment potential 
in vivo [109, 111]. 
 
In contrast to cord blood [112, 113], fetal 
membrane stem cells are presently preserved 
mainly for research. However, as these cells 
gain interest for their regenerative and 
immunomodulatory properties (see chapter 3) 
[29, 114], future medical needs may require 
concomitant application of cord blood and 
placental cells from the same donor. After 
cryopreservation, hAMSC and hCMSC can be 
differentiated at least along the osteogenic 
lineage (Hennerbichler unpublished data). 
However, no conclusive studies are so far 
available on the influence of cryopreservation 
on plasticity. 
 
6.3 Tissue Banking 
The use of amniotic membrane has a hundred 
year history. The first reported clinical use of 
amniotic membrane was in 1910 when it was 
applied in skin transplantation [115]. Shortly 
after, application was expanded to treat burned 
and ulcerated skin [116, 117] and conjunctival 
defects [118]. Since its rediscovery in 1995 
[119], it has been widely applied in 
ophthalmology, surgery and wound healing 
[120]. Besides its nearly unlimited availability, 
easy procurement and low processing costs for 
therapeutic application, many beneficial 
properties of this tissue, including 
bacteriostatic, anti-inflammatory, analgesic, 
wound healing, reepithelialization, reduced 
scarring, and anatomical and vapour barrier 
properties have been reported [56, 121-123]. 
 
Currently, freeze-dried, gamma-sterilized, 
decellularized, glycerol- or cryopreserved 
amniotic membranes are used in 
ophthalmology and wound care [122, 124-
127]. Questions remain as to how these 
different processing and preservation methods 
influence sterility, viability, and growth factor 
release [128, 129] (Hennerbichler S., 
unpublished data). 
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When placentae from caesarean sections were 
collected, 0 of 10 tested were contaminated 
with aerobic or anaerobic bacteria, while 
bacteria were detected in 4 of 10 tested 
naturally born placenta (Hennerbichler S., 
unpublished data). It may therefore be 
preferential to collect placentae from caesarean 
sections. 
 
Membranes were further investigated for 
viability and growth factor release after 
glycerol (50% glycerol) or cryopreservation 
(10% DMSO). Cryopreserved membrane 
retained cell viability and released several 
angiogenic growth factors and cytokines [128, 
129] whereas storage in glycerol at 4°C 
resulted in immediate cell death [128]. Others 
have confirmed that different processing 
methods such as irradiation influence the 
growth factor content of amniotic membrane 
[130]. 
 
CONCLUSION 
 
In 2004, the journal Transplantation ran an 
editorial entitled “Amnion and chorion cells as 
therapeutic agents for transplantation and 
tissue regeneration: a field in its infancy” 
[131]. This editorial referred to one of the first 
reports showing that human fetal membranes 
harbour cells with progenitor/stem cell 
potential that were tolerated by the recipients 
such that they would engraft in animals even 
after xenotransplantation [40]. In this review, 
we have presented recent advances in this field, 
with the aim of defining the placenta derived 
cell subpopulations and their plasticity, as well 
as providing protocols for their isolation and 
differentiation. Finally, the preclinical studies 
reported strongly support the hypothesis that 
placenta holds much promise for the 
development of cell based therapies for clinical 
applications in the near future. 
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Figure 1. Schematic section of the human term placenta. During placenta formation, from the 
maternal side, protrusions of the basal plate within the chorionic villi produce the placental septa, 
which divide the parenchyma into irregular cotyledons. Each cotyledon contains several villi which 
originate from the chorionic plate. Fetal blood vessels are located within the branches of the villi. 
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Figure 2. Cross-sectional representation of human fetal membranes (amnion and chorion). The 
amnion is composed of an epithelial layer of cuboidal and columnar cells which lie on top of a 
mesodermal layer consisting of an upper acellular compact layer and a deeper layer containing 
dispersed fibroblasts. The chorionic membrane consists of a mesodermal layer and a layer of 
extravillous trophoblast cells. (AE: amniotic epithelium; AM: amniotic mesoderm; CM: chorionic 
mesoderm; CT: chorionic trophoblast) 
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Figure 3. Culture of placenta derived stem cell types (LM pictures, 20X magnified). A) Primary 
hAEC culture; B) hAMSC, passage 4; C) hCMSC, passage 4. 
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Table 1. Specific surface antigen expression at passage 2-4 for hAMSC, hCMSC. 
 
Positive ≥ 95% Negative ≤2% 
CD90 CD45 
CD73 CD34 
CD105 CD14 
 HLA-DR 
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Table 2. Human Amniotic Epithelial Cells (hAEC): Isolation protocols, phenotype and in vitro 
differentiation. 
 
Isolation  
Protocols  
 
 
Mechanical peeling of amnion membrane from the underlying 
chorion followed by digestion with: 
Dispase II (2.4U/ml) for 1h OR Trypsin-EDTA (different  
concentrations and incubation times). 
Centrifugation (200x g for 10 min) of  solution containing 
released cells, discarding the remaining membrane. 
[9, 11, 12, 22, 24, 
28, 29, 31, 132] 
Phenotype at 
passage 2-4 
 
Mesenchymal and hematopoietic markers: CD105+, CD90+, 
CD73+, CD44+,CD29+, HLA-ABC+, CD13+, CD10+, 
CD166+, CD49d-, CD49e+, CD117 (+/- very weak signal), 
CD14-, CD34-, CD45-, HLA-DR- 
 
Embryonic cell markers:  SSEA-3+, SSEA-4+, TRA 1-60+, 
TRA 1-81+, SSEA-1- 
 
Others: CD324 (E-Cadherin)+, POU5F1+, SOX2+, CFC1+, 
NANOG+, DPPA3+, PROM1+, PAX6+, FOXD3-, GDF3- 
CD140b+, CD349-, GCTM2+ 
[11, 28, 29, 132] 
(Bühring et al., 
unpublished data) 
Differentiation 
Potential 
 
 
Adipogenic 
DMEM High Glucose (or DMEM/HAM’S 
F12), 10% FBS, 0.5 mM isobutyl-
methylxanthine (IBMX), 1 μM 
dexamethasone, 10 μM insulin, 200 μM 
indomethacin  
[28, 132] 
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Chondrogenic 
DMEM High Glucose, 1% FBS, 6.25ug/mL 
insulin, 10ng/mL TGF-β1, 50ng/mL fresh 
ascorbic acid 
[132] 
DMEM High Glucose (or DMEM/HAM’S 
F12), 10% FBS, 10uM dexamethasone, 
10nM 1-α,25-dehydroxyvitamin D3, 
50ug/mL ascorbic acid, 10mM β-
glycerophosphate  
 
[28] 
 
Osteogenic 
MesenCult Human Osteogenic Stimulatory 
Kit (StemCell Technologies, Vancouver, 
Canada) 
[29] 
Skeletal 
Myogenic 
 
 
 
DMEM/HAM’S F12 (or DMEM High 
Glucose), 10% FBS, 5% human serum (or 
horse serum), 50uM hydrocortisone, (0.1uM 
dexamethasone) 
[28] 
 
DMEM 10% FBS, 55uM 2-
mercaptoethanol, 1mM sodium pyruvate, 
1mM ascorbic acid 2-phosphate 
[11]  
 
Cardiomyogeni
c 
DMEM/HAM’S F12, 10% FBS, 1mM 
ascorbic acid 
 
 [20] 
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DMEM High Glucose, 10% FBS, 30μM all 
trans retinoic acid 
[132] 
DMEM 10% FBS, 55uM 2-
mercaptoethanol, 1mM sodium pyruvate, 
5x10-5M all-trans retinoic acid, 10ng/mL 
FGF-4 
[11] 
Neurogenic 
DMEM/HAM’S F12, 10 % FCS, 
5x10-5M all-trans retinoic acid, 10 ng/ml 
FGF4, N-2, B-27 
[20] 
DMEM 10% FBS, 55uM 2-
mercaptoethanol, 1mM sodium pyruvate, 
10mM nicotinamide on collagen-I coated 
plate 
[11] 
Pancreatic 
 
 
DMEM (or DMEM/HAM’S F12) containing 
N2  supplement (Gibco), 10mM nicotinamide 
 
[28] 
Hepatic 
 
 
 
DMEM 10% FBS, 55uM 2-
mercaptoethanol, 1mM sodium pyruvate, 
dexamethasone 10-7M, 0.1uM insulin for 3 
weeks, addition of 1mM phenobarbital for 
the final 3 days, on collagen-I coated plate 
[11] 
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DMEM 10% FBS, 20ng/mL HGF, 10ng/mL 
FGF-2, 10ng/mL oncostastin M, 100nM 
dexamethasone, 10U/mL heparin sodium 
salt 
[22]  
 
 
DMEM/HAM’S F12, 10 % FCS+0.1 uM 
insulin, 1 x 10-7M dexamethasone 
[20] 
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Table 3. Human Amniotic Mesenchymal Stromal Cells (hAMSC): Isolation protocols, phenotype 
and in vitro differentiation. 
 
Isolation  
Protocols 
 
 
Mechanical peeling of amnion membrane from the underlying 
chorion followed by digestion with varying concentrations of 
collagenase (0.75-2 mg/Ml) and DNase (20-75μg/mL) for 30-
120 min at 37°C  
[27-29, 31-33, 
37] (Zisch et al,  
unpublished,) 
Phenotype at 
passage 2-4 
 
 
Mesenchymal and hematopoietic markers: CD105+, CD90+, 
CD73+, CD44+, CD29+, HLA-ABC+, CD13+, CD10+, 
CD49c+, CD49d+, CD49e+, CD54+, CD166+, CD271low, 
CD14-, CD34-, CD45-, CD31-, HLA-DR-,  
CD133-, CD3- 
 
Embryonic cell markers: 
Oct-4+ 
 
Others:  
CD349+, CD140b+, CD324 (E-cadherin)- 
[26, 28, 29, 31, 
35] 
(Bühring et al., 
unpublished 
data) 
DMEM, 10% FCS, 0.5mM IBMX, 200uM 
indomethacin, 10-6M dexamethasone, 
10ug/mL insulin 
[28, 35] 
Adipogenic 
Bullet Kit Adipogenic Differentiation Media 
(Cambrex) 
[31] 
Differentiation 
Potential 
Chondrogenic 
DMEM High Glucose, 1% FBS, 6.25ug/mL 
insulin, 10ng/mL TGF-β1, 50ng/mL fresh 
ascorbic acid 
[28] 
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DMEM, 6.25ug/mL insulin, 6.25ug/mL 
transferring, 6.25ug/mL selenous acid, 
5.33ug/ml linolenic acid, 1.25 mg/mL BSA, 
0.35mM proline, 1mM sodium pyruvate, 10-
7 M dexamethasone, 0.1mM l-ascorbic acid-
2-phosphate supplemented with 10ng/mL 
transforming growth-β-3. 
[35] 
DMEM, 100 nM dexamethasone, 50 μg/ml 
L-ascorbic acid 2-phosphate, 1mM sodium 
pyruvate, 40 μg/ml proline, ITS (5 μg/mL 
insulin, 5 μg/ml transferrin, 5 ng/ml 
selenous acid), 5 ng/ml TGFβ1 
[31] 
DMEM High Glucose, 10% FBS, 10mM β-
glycerophosphate, 50-200 ug/mL ascorbic 
acid, 10-8M dexamethasone, 1,α25-
dihydroxyvitamin-D3  
 
[24, 26-28, 35, 
37] 
Osteogenic 
Commercial Media: MesenCult Human 
Osteogenic Stimulatory Kit (StemCell 
Technologies, Vancouver, Canada); 
BulletKit Osteogenic Differentiation Media 
(Cambrex) 
[29, 31] 
Skeletal 
Myogenic 
DMEM High Glucose, 10% FS, 5% horse 
serum, 50uM hydrocortisone, 0.1uM 
dexamethasone  
[132] 
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DMEM, 5% FBS, 40 MCDB-201, ITS-
LA*BSA 100x, 10-8M dexamethasone, 10-
8M ascorbic acid-2-phosphate, 10ng/mL 
bFGF, 10ng/mL VEGF, 10ng/mL insulin 
like growth factor-1 
[35] 
Angiogenic 
 
Matrigel adherence, VEGF 50ng/mL, 2% 
FBS,   
[35] 
DMEM High Glucose, 10% FBS, 30μM all 
trans retinoic acid 
[28] 
Neurogenic 
DMEM, 100uM butylated hydroxyanisol 
(BHA), 10uM forskolin, 2% DMSO, 5U/mL 
heparin, 5nM K252a, 25mM KCl, 2mM 
valproic acid, 1x N2 supplement, 10ng/mL 
bFGF, 10ng/mL PDGF-BB 
[27] 
Pancreatic 
DMEM containing N2  supplement (Gibco), 
10mM nicotinamide 
[24] 
DMEM 10% FBS, 10ng/mL bFGF, 
50ng/mL activin A 
[37] 
Cardiomyoge
nic 
Mixed ester of hyaluronan with butyric and 
retinoic acid (HBR) treatment 
[79] 
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Table 4. Human Chorionic Mesenchymal Stromal Cells (hCMSC): Isolation protocols, phenotype 
and in vitro differentiation 
 
Isolation  
Protocols 
 
 
Mechanical removal of surrounding layers after treatment with 2.4 
U/ml dispase II at 37°C, followed by 1-3h treatment with 
Worthington collagenase II (270U/ml) or collagenase A 
(0.83mg/ml). 
[28, 31] 
Phenotype at 
passage 2-4 
 
 
Mesenchymal and hematopoietic markers: CD105+, CD90+, 
CD73+, CD44+, CD29+, HLA-ABC+, CD13+, CD166+, 
CD49e+, CD271low, CD10+, CD14-, CD34-,CD45-, CD117-, 
CD133-, HLA-DR- 
 
Embryonic stem cell markers: SSEA-4-/+ 
 
Others: CD349+, CD140b+, CD324- 
 
[28, 31, 133] 
(Bühring et al., 
unpublished 
data) 
DMEM High Glucose, 10% FBS, 0.5 mM 
isobutyl-methylxanthine (IBMX), 1 μM 
dexamethasone, 10 μM insulin, 200 μM 
indomethacin  
[28] 
Adipogenic 
Bullet Kit Adipogenic Differentiation Media 
(Cambrex)) 
[31] 
Differentiation 
Potential 
 
 
Chondrogenic 
DMEM High Glucose, 1% FBS, 6.25ug/mL 
insulin, 10ng/mL TGF-β1, 50ng/mL fresh 
ascorbic acid 
[28]  
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DMEM, 100 nM dexamethasone, 50 μg/ml L-
ascorbic acid 2-phosphate, 1mM sodium 
pyruvate, 40 μg/ml proline, ITS (5 μg/mL 
insulin, 5 μg/ml transferrin, 5 ng/ml selenous 
acid), 5 ng/ml TGFβ1 
[31] 
10μM dexamethasone, 10nM 1α, 25-
dihydroxyvitamin D3, 50μg/ml ascorbic acid, 
10mM β-glycerophosphate  
[28] 
 
Osteogenic 
BulletKit Osteogenic Differentiation Media 
(Cambrex) 
[31] 
Skeletal 
Myogenic 
DMEM High Glucose, 10% FBS, 5% horse 
serum, 50uM hydrocortisone, 0.1uM 
dexamethasone 
[28, 31] 
Neurogenic 
DMEM High Glucose, 10% FBS, 30μM all 
trans retinoic acid 
[28] 
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